Welcome to our dedicated page for Lumexa Imaging Holdings news (Ticker: LMRI), a resource for investors and traders seeking the latest updates and insights on Lumexa Imaging Holdings stock.
Lumexa Imaging Holdings, Inc. reports developments tied to its nationwide outpatient medical imaging platform. The company operates diagnostic imaging centers and provides radiology interpretation services, with imaging modalities that include MRI, CT, PET, X-ray, ultrasound and mammography.
Recurring LMRI news covers financial and operating results, conference-call schedules, de novo center openings, joint venture and health-system relationships, leadership appointments, investor conference participation and clinical quality initiatives. Company updates also address growth strategy, advanced imaging volume trends, payer-network activity, balance-sheet actions and the technology used to support patient engagement in radiology reporting.
Lumexa Imaging (NASDAQ: LMRI) announced a strategic joint venture with Hospital for Special Surgery (HSS), a global leader in musculoskeletal health. This is Lumexa’s ninth joint venture and strengthens its presence in the New York City metro area.
The partners plan to expand access to advanced outpatient imaging, leveraging HSS subspecialized radiology expertise and Lumexa’s joint venture model to support long-term growth, de novo development, acquisitions, and enhanced patient and provider access.
Lumexa Imaging (Nasdaq: LMRI) reported first quarter 2026 results and reiterated full-year guidance. Q1 consolidated revenues were $252.5 million, up 3.1% year over year, with system-wide revenue growth of 4.0%.
Same-center advanced imaging volumes grew 5.6%, and advanced procedures rose to 31.1% of consolidated procedures. Net income was $1.7 million versus a net loss of $7.7 million a year ago. Adjusted EBITDA was $51.2 million with a 20.3% margin; GAAP EPS was $0.02 and Adjusted EPS $0.18.
The company announced four additional centers (two tuck-in acquisitions and two de novos). For 2026, Lumexa continues to expect consolidated revenues of $1.045–$1.097 billion, Adjusted EBITDA of $234–$242 million, and Adjusted EPS of $0.71–$0.77 per share.
Lumexa Imaging (NASDAQ: LMRI) is expanding its outpatient imaging network with four new centers in 2026, in South Carolina, North Carolina, Pennsylvania and Florida.
Two sites come via acquisitions with Advocate Health and UPMC, bringing the footprint to 190+ centers nationwide and marking entry into Pennsylvania.
Lumexa Imaging (NASDAQ: LMRI) will release first quarter 2026 financial and operational results after market close on Tuesday, May 12, 2026. The company will host a conference call and live webcast at 5:00 p.m. ET. The live audio webcast will be available at the investor relations site and a replay will be accessible for about one year.
Lumexa Imaging (NASDAQ: LMRI) appointed Kyle Lynch as Chief Growth Officer, effective April 20, 2026. Lynch will lead enterprise growth via joint ventures, acquisitions, and de novo development and oversee opportunity origination, transaction execution, and post-close value realization.
He will also lead the Sales Center of Excellence to standardize metrics, boost sales productivity, and drive referral and same-center performance across Lumexa Imaging’s national outpatient imaging platform.
Lumexa Imaging (Nasdaq: LMRI) reported preliminary, unaudited fourth-quarter and full-year 2025 results and reiterated 2026 guidance on March 26, 2026. Q4 revenue was $267.7 million, up 7.9% year-over-year, with Adjusted EBITDA of $63.8 million (23.8% margin). Full-year 2025 revenue was $1.023 billion and Adjusted EBITDA was $230.2 million. The company cut leverage from 5.5x to 3.5x and added ten facilities in 2025. 2026 guidance: revenue $1.045–1.097 billion and Adjusted EBITDA $234–242 million; Adjusted EPS $0.71–0.77.
Lumexa Imaging (NASDAQ: LMRI) announced executive participation in three investor conferences in March 2026, including speaker times and formats.
Caitlin Zulla, CEO, and Tony Martin, CFO, will present at Raymond James (3:25pm ET, Mar 2), speak at Leerink fireside chat (8:40am ET, Mar 9), and speak at Barclays fireside chat (3:30pm ET, Mar 10). A webcast and presentation materials will be available at the company investor site.
Lumexa Imaging (NASDAQ: LMRI) announced that Jennifer L. Kemp, MD, Chair of its Center for Quality, was elected to the Radiological Society of North America (RSNA) Board of Directors and will serve as board liaison for government relations.
The company highlights Dr. Kemp's focus on patient-centered care and notes Lumexa's use of Scanslated AI-driven software, which has delivered over 2 million reports to patients and yielded a 99% positive survey response on likelihood to choose Lumexa centers.
Lumexa Imaging (NASDAQ: LMRI) set a company record by opening nine de novo outpatient imaging centers in 2025, including two centers that opened in December in Anderson, South Carolina and Cotswold, North Carolina. With these additions, Lumexa operates more than 185 centers across 13 states. Prior 2025 openings occurred in New York, South Carolina and Texas. Management said the de novo strategy targets high-growth MSAs and intends to continue expansion in 2026.
Lumexa Imaging (NASDAQ: LMRI) announced that CEO Caitlin Zulla and CFO Tony Martin will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for 7:30 AM PST on Monday, January 12, 2026. A live webcast and presentation materials will be available at the company investor site: https://ir.lumexaimaging.com.